How much revenue does NGeneBio make?

NGeneBio reported 21.24 billion KRW in revenue for fiscal year 2025, up 273.2% from 5.69 billion KRW in fiscal year 2024.

Where does NGeneBio make most of its revenue?

South Korea: 55% of revenue by region in fiscal year 2024, followed by Overseas (45%).

What companies are similar to NGeneBio?

Listed companies of a similar size in the same industry (DNA testing equipment) include Genesystem Co., Ltd. (363250.KQ), GeneMatrix Inc. (109820.KQ), Celestra Inc. (352770.KQ).

NGeneBio Co., Ltd. (354200.KQ) Stock

About NGeneBio Co., Ltd.

NGeneBio Co., Ltd. develops in vitro diagnostics companion diagnostics products and bioinformatics software. It offers BRCAaccuTest and BRCAaccuTest PLUS are reagent kits for breast and ovarian cancer, and hereditary breast and ovarian cancer syndrome; HEMEaccuTest, a clinical NGS kit for hematological malignancies, such as acute myeloid leukemia, acute lymphoid leukemia, myelodysplastic/myeloprol...

At a glance

NGeneBio reported revenue of 21.24 billion KRW for fiscal year 2025, up 273.2% from fiscal year 2024, and net income of -5.54 billion KRW. South Korea was its largest region in fiscal year 2024, with 55% of revenue.

Figures from company filings; latest fiscal year ended December 31, 2025.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.